Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received a consensus rating of “Buy” from the twenty-two analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $182.71.
A number of analysts have issued reports on the stock. BidaskClub cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. ValuEngine cut shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 18th. Zacks Investment Research upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a research note on Tuesday, April 16th. Mizuho reiterated a “hold” rating and issued a $147.00 target price (up from $137.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $185.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, March 26th.
In related news, SVP Paul Treacy sold 874 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $139.50, for a total transaction of $121,923.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the business’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total transaction of $933,240.00. Following the transaction, the executive vice president now directly owns 40,401 shares in the company, valued at approximately $5,656,140. The disclosure for this sale can be found here. Insiders sold 11,668 shares of company stock valued at $1,606,567 over the last 90 days. 3.90% of the stock is owned by corporate insiders.
NASDAQ JAZZ opened at $129.57 on Tuesday. The company has a quick ratio of 3.42, a current ratio of 3.57 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of 10.59, a price-to-earnings-growth ratio of 1.06 and a beta of 1.16. Jazz Pharmaceuticals has a 12-month low of $113.52 and a 12-month high of $184.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.61. The firm had revenue of $476.46 million during the quarter, compared to analysts’ expectations of $459.48 million. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company’s revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.95 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals will post 13.19 EPS for the current fiscal year.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: Analyst Ratings Trading
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.